Clinical Trial Site

Omaha, Nebraska 68198

2 studies enrolling now · 10 studies all time

What they study most

Hearing Loss, Sensorineural, Hereditary Transthyretin-mediated (ATTRv) Amyloidosis, High Cardiovascular Risk, High Risk Cardiovascular Disease, Hypertension, Noise Induced Hearing Loss, Polyneuropathy, Presbycusis, Prostate Cancer Metastatic, Sensorineural Hearing Loss, Sudden Hearing Loss, Sudden Sensorineural Hearing Loss

Studies at this site

• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease — Recruiting now
• Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) — Completed
• A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Enrolling by invitation
• A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis — Running, not enrolling
• Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer — Completed
• FX-322 in Adults With Stable Sensorineural Hearing Loss — Completed
• FX-322 in Adults With Acquired Sensorineural Hearing Loss — Completed
• A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation — Completed
• FX-322 in Adults With Age-Related Sensorineural Hearing Loss — Completed
• FX-322 in Adults With Severe Sensorineural Hearing Loss — Completed